Complete remission in an advanced hepatocellular carcinoma patient with AXIN1 mutation after systemic therapy: A case report
Primary hepatocellular carcinoma (HCC) is a common malignancy with high morbidity and mortality. Despite progress in systemic therapies, survival in advanced HCC remains poor due to patient heterogeneity and individual differences, necessitating a personalized approach rather than relying solely on...
Saved in:
Main Authors: | Yihong Ran, Xiaozhun Huang, Xu Che, Dong Chen |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-01-01
|
Series: | Heliyon |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2405844025003901 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Combination of D-TACE-HAIC, Lenvatinib, and PD-1 Inhibitors Shows Significant Clinical Efficacy in Patients with Unresectable Hepatocellular Carcinoma
by: Wu Y, et al.
Published: (2025-02-01) -
Clinical Outcomes of Hepatic Arterial Infusion Chemotherapy Plus Lenvatinib and Tislelizumab for Treating Hepatocellular Carcinoma and Type IV Portal Vein Tumor Thrombus
by: Li X, et al.
Published: (2025-01-01) -
Lenvatinib and tislelizumab versus atezolizumab and bevacizumab in combination with TAE-HAIC for unresectable hepatocellular carcinoma with high tumor burden: a multicenter retrospective cohort study
by: Hongjie Cai, et al.
Published: (2025-02-01) -
A new prognostic model for predicting overall survival and progression-free survival in unresectable hepatocellular carcinoma treated with the FOLFOX-HAIC regimen based on patient clinical characteristics and blood biomarkers
by: Qiuyao Zeng, et al.
Published: (2025-01-01) -
Hepatic arterial infusion chemotherapy combined with systemic therapy sequentially or simultaneously for advanced hepatocellular carcinoma
by: Yu-zhe Cao, et al.
Published: (2024-11-01)